Cargando…

Comparison of Blood Glucose Variability Between Exenatide and Biphasic Insulin Aspart 30 in Chinese Participants with Type 2 Diabetes Inadequately Controlled with Metformin Monotherapy: A Multicenter, Open-Label, Randomized Trial

INTRODUCTION: To compare blood glucose variability (GV) in Chinese participants with type 2 diabetes mellitus (T2DM) whose blood glucose levels are inadequately controlled with metformin monotherapy after twice-daily exenatide or biphasic insulin aspart 30 (BIAsp30). METHODS: In this 16-week multice...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Li, Liu, Xiangyang, Yang, Wenjuan, Lai, Jingbo, Yu, Xinwen, Liu, Jianrong, Gao, Xiling, Ming, Jie, Ma, Kaiyan, Xu, Jing, Tian, Zhufang, He, Qingzhen, Ji, Qiuhe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7509011/ https://www.ncbi.nlm.nih.gov/pubmed/32856226 http://dx.doi.org/10.1007/s13300-020-00904-z

Ejemplares similares

Comparison of exenatide with biphasic insulin aspart 30 on glucose variability in type 2 diabetes: study protocol for a randomized controlled trial
por: Xu, Shaoyong, et al.
Publicado: (2016)

Effect and Safety of Pioglitazone-Metformin Tablets in the Treatment of Newly Diagnosed Type 2 Diabetes Patients with Nonalcoholic Fatty Liver Disease in Shaanxi Province: A Randomized, Double-Blinded, Double-Simulated Multicenter Study
por: Jianfang, Fu, et al.
Publicado: (2023)

Comparison of Exenatide and Metformin Monotherapy in Overweight/Obese Patients with Newly Diagnosed Type 2 Diabetes
por: Liu, Jia, et al.
Publicado: (2017)

15 Years of Experience with Biphasic Insulin Aspart 30 in Type 2 Diabetes
por: Liebl, Andreas, et al.
Publicado: (2018)

Effectiveness and safety of Bifidobacterium and berberine in human hyperglycemia and their regulatory effect on the gut microbiota: a multi-center, double-blind, randomized, parallel-controlled study
por: Ming, Jie, et al.
Publicado: (2021)

Subject‐driven titration of biphasic insulin aspart 30 twice daily is non‐inferior to investigator‐driven titration in Chinese patients with type 2 diabetes inadequately controlled with premixed human insulin: A randomized, open‐label, parallel‐group, multicenter trial
por: Yang, Wenying, et al.
Publicado: (2015)

Biphasic insulin aspart 30/70 (BIAsp 30) in the treatment of type 1 and type 2 diabetes
por: Valensi, Paul
Publicado: (2009)

Biphasic Insulin Aspart 30/70: Pharmacokinetics and Pharmacodynamics Compared With Once-Daily Biphasic Human Insulin and Basal-Bolus Therapy
por: Heise, Tim, et al.
Publicado: (2009)

The effect of alogliptin on pulmonary function in obese patients with type 2 diabetes inadequately controlled by metformin monotherapy
por: Tai, He, et al.
Publicado: (2016)

Comparison of daily glucose excursion by continuous glucose monitoring between type 2 diabetic patients receiving biphasic insulin aspart 30 or biphasic human insulin 30
por: Ohta, Akio, et al.
Publicado: (2011)

Exenatide Twice Daily Versus Premixed Insulin Aspart 70/30 in Metformin-Treated Patients With Type 2 Diabetes: A randomized 26-week study on glycemic control and hypoglycemia
por: Gallwitz, Baptist, et al.
Publicado: (2011)

The Efficacy and Safety of Imeglimin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy
por: Fouqueray, Pascale, et al.
Publicado: (2013)

Safety and efficacy of ertugliflozin in Asian patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: VERTIS Asia
por: Ji, Linong, et al.
Publicado: (2019)

Ten Years of Experience with Biphasic Insulin Aspart 30: From Drug Development to the Latest Clinical Findings
por: Liebl, Andreas, et al.
Publicado: (2012)

Safety and Effectiveness of Switching from a Basal-only to Biphasic Insulin Aspart 30 Insulin Regimen
por: Haddad, Jihad, et al.
Publicado: (2013)

Exenatide with Metformin Ameliorated Visceral Adiposity and Insulin Resistance
por: Du, Xuan, et al.
Publicado: (2018)

Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly alone, or dapagliflozin alone added to metformin monotherapy in subgroups of patients with type 2 diabetes in the DURATION‐8 randomized controlled trial
por: Frías, Juan P., et al.
Publicado: (2018)

The effect of alogliptin on pulmonary function in obese patients with type 2 diabetes inadequately controlled by metformin monotherapy: Erratum
Publicado: (2016)

Clinical experience of switching from biphasic human insulin to biphasic insulin aspart 30 in Indian patients with type 2 diabetes in the A(1)chieve study
por: Das, A. K., et al.
Publicado: (2015)

Safety and Effectiveness of Biphasic Insulin Aspart 30 in Different Age-Groups: A(1)chieve Sub-Analysis
por: Khamseh, Mohammad Ebrahim, et al.
Publicado: (2013)

Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly, or dapagliflozin, added to metformin monotherapy, on body weight, systolic blood pressure, and triglycerides in patients with type 2 diabetes in the DURATION‐8 study
por: Jabbour, Serge A., et al.
Publicado: (2018)

Comparison of a soluble co-formulation of insulin degludec/insulin aspart vs biphasic insulin aspart 30 in type 2 diabetes: a randomised trial
por: Niskanen, Leo, et al.
Publicado: (2012)

Insulin degludec/insulin aspart vs biphasic insulin aspart 30 twice daily in Japanese patients with type 2 diabetes: A randomized controlled trial
por: Onishi, Yukiko, et al.
Publicado: (2016)

Efficacy and safety of alogliptin versus acarbose in Chinese type 2 diabetes patients with high cardiovascular risk or coronary heart disease treated with aspirin and inadequately controlled with metformin monotherapy or drug‐naive: A multicentre, randomized, open‐label, prospective study (ACADEMIC)
por: Gao, Bin, et al.
Publicado: (2022)

Comparison of Premixed Human Insulin 30/70 to Biphasic Aspart 30 in Well-Controlled Patients with Type 2 Diabetes Using Continuous Glucose Monitoring
por: Margaritidis, Charalampos, et al.
Publicado: (2021)

Treatment Compliance with Fixed-Dose Combination of Vildagliptin/Metformin in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Metformin Monotherapy: A 24-Week Observational Study
por: Rombopoulos, Grigorios, et al.
Publicado: (2015)

Review of biphasic insulin aspart in the treatment of type 1 and 2 diabetes
por: Raja-Khan, Nazia, et al.
Publicado: (2007)

A randomized controlled trial of the efficacy and safety of twice-daily saxagliptin plus metformin combination therapy in patients with type 2 diabetes and inadequate glycemic control on metformin monotherapy
por: White, Judith L, et al.
Publicado: (2014)

Efficacy and safety of sitagliptin compared with sulfonylurea therapy in patients with type 2 diabetes showing inadequately controlled glycosylated hemoglobin with metformin monotherapy: A meta-analysis
por: HOU, LIQIONG, et al.
Publicado: (2015)

Randomized Trial of Continuous Subcutaneous Delivery of Exenatide by ITCA 650 Versus Twice-Daily Exenatide Injections in Metformin-Treated Type 2 Diabetes
por: Henry, Robert R., et al.
Publicado: (2013)

Efficacy and safety of insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Chinese adults with type 2 diabetes: A phase III, open‐label, 2:1 randomized, treat‐to‐target trial
por: Yang, Wenying, et al.
Publicado: (2019)

Cost-effectiveness of insulin degludec/insulin aspart versus biphasic insulin aspart in Chinese population with type 2 diabetes
por: Luo, Qiong, et al.
Publicado: (2022)

28‐week, randomized, multicenter, open‐label, parallel‐group phase III trial to investigate the efficacy and safety of biphasic insulin aspart 70 thrice‐daily injections vs twice‐daily injections of biphasic insulin aspart 30 in patients with type 2 diabetes
por: Kadowaki, Takashi, et al.
Publicado: (2010)

Efficacy and safety of biphasic insulin aspart and biphasic insulin lispro mix in patients with type 2 diabetes: A review of the literature
por: Kumar, Ajay
Publicado: (2016)

Improved Glycaemic Control with Biphasic Insulin Aspart 30 in Type 2 Diabetes Patients Failing Oral Antidiabetic Drugs: PRESENT Study Results
por: Güler, Serdar, et al.
Publicado: (2009)

Switching from basal or basal-bolus insulin to biphasic insulin aspart 30: Results from the Indian cohort of the A(1) chieve study
por: Bhattacharyya, Arpandev, et al.
Publicado: (2014)

Biphasic insulin Aspart 30 vs. NPH plus regular human insulin in type 2 diabetes patients; a cost-effectiveness study
por: Farshchi, Amir, et al.
Publicado: (2016)

Intensification to biphasic insulin aspart 30/70 (BIAsp 30, NovoMix® 30) can improve glycaemic control in patients treated with basal insulins: a subgroup analysis of the IMPROVE™ observational study
por: Gumprecht, J, et al.
Publicado: (2009)

Comparison of exenatide alone or combined with metformin versus metformin in the treatment of polycystic ovaries: a systematic review and meta-analysis
por: Hu, Yan, et al.
Publicado: (2023)

Composite cardiovascular risk and BMI affected comparative profiles of BIAsp 30 + metformin vs BIAsp 30 monotherapy: a MERIT post-hoc analysis
por: Guo, Lixin, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_buk0sij3o8hhdin4o0mhn1tcmi